Assessment of the Intervention Effectiveness of Branched-chain Amino Acids(BCAA) Combined With Medium-chain Fatty Acid(MCFA) Products in Sarcopenia Among Middle-aged and Elderly Individuals
- Disease/Condition
- Sarcopenia
- Drug/Device/Intervention
- nutritional supplements
- Study type
- Interventional
- Intervention type
- combination product
- Primary sponsor
- National Taiwan University Hospital
- Location
- Taipei, Taiwan
- Phase
- N/A
- Start date
- Oct 01, 2023
- End date
- Sep 30, 2024
- Enrollment
- 80 participants
the scale of sarcopenia,the scale of sarcopenia,the scale of sarcopenia
Taiwan entered an aging society in 2018 and is expected to transition into a super-aged
 society by 2025. With the increasing elderly population, age-related diseases pose urgent
 challenges to modern society. According to the Ministry of Health and Welfare's National
 Health Statistics in 2018, the prevalence of sarcopenia in Taiwan among individuals aged 65
 and older is 23.6% for males and 18.6% for females. Sarcopenia, characterized by the loss of
 skeletal muscle mass due to aging, coupled with decreased muscle strength and/or reduced
 physical performance, poses a significant risk for disability, decreased quality of life, and
 increased mortality.
 
 Existing research indicates that appropriate nutrition and exercise can slow the onset of
 sarcopenia and even increase muscle mass to reverse its effects. This study is an
 interventional clinical trial recruiting middle-aged and elderly patients with sarcopenia or
 pre-sarcopenia. The intervention involves a combination of branched-chain amino acids and
 medium-chain triglyceride products, and the study aims to assess the effectiveness of this
 intervention for sarcopenia in middle-aged and elderly individuals.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06376266
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06376266 through Pure Global AI's free database. This phase not specified trial is sponsored by National Taiwan University Hospital and is currently Recruiting. The study focuses on Sarcopenia. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.